Eloralintide and the amylin pathway: how it works and where the research stands
Eloralintide is among the newest names in the Peptivia catalog, and interest in it has risen quickly since the phase 2 trial results were published. This article covers three things: what amylin is, how eloralintide makes use of its pathway, and how the research is progressing.
Amylin, the fullness signal from the pancreas
Amylin is a 37 amino acid peptide hormone released by the beta cells of the pancreas together with insulin every time you eat. Its main role is in the brain, especially in the part of the brainstem called the area postrema. There amylin helps signal that the body has eaten enough, slows gastric emptying, and holds back the release of glucagon after a meal. As a result, the next portion tends to be smaller.
Its receptor is also unique. The amylin receptor is formed from the calcitonin receptor paired with a companion protein called RAMP. Because of that, many molecules that touch the amylin pathway also touch the calcitonin receptor.
Where eloralintide sits
Natural amylin clumps quickly and breaks down quickly, so it is hard to use directly. The first amylin analog approved in the United States, pramlintide, is injected before every meal. Eloralintide (research code LY3841136) was developed by Eli Lilly as an amylin receptor agonist that is selective and stable enough to be given once a week.
The word selective matters here. Eloralintide is designed to lean more toward the amylin receptor than the calcitonin receptor. This sets it apart from other amylin analogs such as Cagrilintide, which works on both receptors at once. The phase 3 trial will give a fuller picture of what this difference means.
| Molecule | Receptor target | Status |
|---|---|---|
| Natural amylin | Amylin and calcitonin | A body hormone, breaks down quickly |
| Pramlintide | Amylin and calcitonin | Approved in the US for diabetes, injected at every meal |
| Cagrilintide | Amylin and calcitonin | Clinical trials are still ongoing |
| Eloralintide | More selective for amylin | Phase 3 trial running since 2026 |
Phase 2 trial results
The phase 2 trial results were published in the journal The Lancet in November 2025. This randomized, double-blind trial involved 263 adults with obesity or overweight without type 2 diabetes, over 48 weeks, with a comparison group. All treatment groups reached the study's primary target, which was a greater reduction in body weight than the comparison group. These results are what got eloralintide so widely talked about.
The phase 3 trial now under way
The phase 3 trial named ENLIGHTEN-1 began in February 2026 with a plan for around 1,980 participants. A trial of this size will give a broader picture of eloralintide over a longer period. If you are interested in other amylin pathways, Retatrutide and Cagrilintide covers how two pathways are combined.
Practical questions before ordering are summed up in the checklist for buying peptides online safely.
The product details are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.
